Criticalkare Pharma

Ujvira 100mg Injection is a targeted therapy containing the active constituent trastuzumab emtansine. The U.S. Food and Drug Administration (FDA) approved trastuzumab emtansine on February 22, 2013, for treating patients with HER2-positive metastatic breast cancer who have previously received trastuzumab and chemotherapy. This medication is not recommended for adolescents and children under 18. Before taking this medicine, it is vital to inform your doctor if you have any blood clot disorders, liver disorders, or allergies.

Uses
Advanced and metastatic breast cancer

Storage
Store between 2˚C and 8˚C.
Keep Ujvira 100mg Injection out of sight and reach of children.

Side Effects
Heart ProblemsAllergic reactionsKidney problemsBreathing difficultiesFeverVisual disturbancesNose bleeds or runny noseHair lossDizzinessNail disordersWeight lossLoss of appetiteBruisingDry mouthLiver  inflammationMuscle painAsthma/lung disorders

Ujvira 160mg Injection is a targeted therapy containing the active constituent trastuzumab emtansine. It is used to treat adults with a type of breast cancer (human epidermal growth factor receptor 2 positive breast cancer) that has spread to other parts of the body or has not improved after treatment with other medications. It is a combination of two drugs: trastuzumab, which is a monoclonal antibody that targets HER2-positive breast cancer cells, and emtansine, which is a chemotherapy drug that destroys cancer cells. This medicine is also given after surgery to kill any cancer cells left in the breast (adjuvant therapy). This medication is not recommended for adolescents and children under 18. Before taking this medicine, it is vital to inform your doctor if you have any blood clot disorders, liver disorders, or allergies.

Uses
Breast cancer (human epidermal growth factor receptor 2 positive breast cancer)

Storage
Store between 2˚C and 8˚C.
Keep Ujvira 160mg Injection out of sight and reach of children.

Side Effects
Heart ProblemsAllergic reactionsKidney problemsBreathing difficultiesFeverVisual disturbancesNose bleeds or runny noseHair lossDizzinessNail disordersWeight lossLoss of appetiteBruisingDry mouthLiver  inflammationMuscle painAsthma/lung disorders

Kadcyla 100mg Injection consists of the active ingredient Ado-Trastuzumab emtansine. It is a prescription medication used to treat HER2-positive breast cancer that has spread to other parts of the body or has not responded to other treatments. It is a combination of two drugs: trastuzumab, which is an antibody that targets HER2 receptors, and emtansine, which is a chemotherapy drug that kills cancer cells. It is indicated to treat breast cancer in the early stages as well as advanced stages, where patients develop recurrence within six months of chemotherapy treatment. This medication acts against tumors that produce more than the normal amount of a certain protein (known as the HER2 protein).
Patients with residual breast cancer after chemotherapy treatment and HER2-targeted therapy have a poorer prognosis than those with no residual cancer. Report to your physician immediately if you experience side effects such as allergic reactions, unusual bleeding, etc. This medication does not show any adverse effects on the kidney. In rare cases, an infusion reaction is seen. Like all other medications, it shows mild side effects like nausea, vomiting, diarrhea, and hair loss.

Uses
Advanced and metastatic breast cancerMetastatic gastric cancer

Storage
Kadcyla 100mg Injection should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F).Protected from light.Keep it in its original packaging until it is ready to be used.Keep reaching out of the reach of children and pets.It should be disposed of properly.

Side Effects
Infusion reactions, including fever, chills, rash, or difficulty breathingLung problems, including shortness of breath, cough, or feverHeart problems, including heart failure or abnormal heart rhythmsSevere bleeding or bruisingNerve damage, including numbness, tingling, or weaknessSevere allergic reactionsFatigueNauseaConstipationMuscle or joint painHeadacheFeverLow platelet countHigh liver enzyme levelsLow red blood cell countLoss of appetiteRash or itching

Kadcyla 160mg Injection consists of the active ingredient Ado-Trastuzumab emtansine. It is a prescription medication used to treat HER2-positive breast cancer that has spread to other parts of the body or has not responded to other treatments. It is a combination of two drugs: trastuzumab, which is an antibody that targets HER2 receptors, and emtansine, which is a chemotherapy drug that kills cancer cells. It is indicated to treat breast cancer in the early stages as well as advanced stages, where patients develop recurrence within six months of chemotherapy treatment. This medication acts against tumors that produce more than the normal amount of a certain protein (known as the HER2 protein).
Patients with residual breast cancer after chemotherapy treatment and HER2-targeted therapy have a poorer prognosis than those with no residual cancer. Report to your physician immediately if you experience side effects such as allergic reactions, unusual bleeding, etc. This medication does not show any adverse effects on the kidney. In rare cases, an infusion reaction is seen. Like all other medications, it shows mild side effects like nausea, vomiting, diarrhea, and hair loss.

Uses
Advanced and metastatic breast cancerMetastatic gastric cancer

Storage
Kadcyla 160mg Injection should be stored in the refrigerator at 2°C to 8°C (36°F to 46°F).Protected from light.Keep it in its original packaging until it is ready to be used.Keep reaching out of the reach of children and pets.It should be disposed of properly.

Side Effects
Infusion reactions, including fever, chills, rash, or difficulty breathingLung problems, including shortness of breath, cough, or feverHeart problems, including heart failure or abnormal heart rhythmsSevere bleeding or bruisingNerve damage, including numbness, tingling, or weaknessSevere allergic reactionsFatigueNauseaConstipationMuscle or joint painHeadacheFeverLow platelet countHigh liver enzyme levelsLow red blood cell countLoss of appetiteRash or itching